CDH3 and glioblastoma: In this work, using in vitro and in vivo models, as well as patient‐derived samples, we have established CDH3/P‐cadherin as a novel oncogenic player in human GBM, deciphering its functional roles, and as a novel prognostic biomarker predictive of shorter survival in GBM patients.